Taiwan approves use of oral CDK4/6 suppressants
Taiwan’s health authorities have approved the use of oral CDK4/6 targeting suppressants to treat HER2 negative breast cancer for late stage/recurrence metastasis patients.
CDK4/6 are cyclin dependent kinases 4/6. Inhibitors of CDK4/6 trigger anti-tumor immunity and induce tumor cell cycle arrest.
Each year, 2,500 new cases of late stage/recurrence metastasis breast cancer patients are diagnosed, 60% of them are HER2 negative breast cancer sufferers.